The fund has been granted to the Israeli R&D subsidiary of Prolor for the biobetter version of human growth hormone, hGH-CTP.
Prolor is responsible to pay back the OCS the sum of the grant plus accrued interest through a series of payments that would begin only when hGH-CTP or other products that Prolor develops with its CTP technology begin to generate commercial revenues.
The Phase II trial of hGH-CTP showed reduction in the required hGH dosing frequency from the one injection per day required currently to a single weekly injection.
The company intends to begin a Phase III trial of hGH-CTP in adults with growth hormone deficiency in 2012.